Compare CDNA & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDNA | ANAB |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2007 | 2015 |
| Metric | CDNA | ANAB |
|---|---|---|
| Price | $24.08 | $54.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $28.00 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 652.3K | 482.8K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 0.05 | N/A |
| Revenue | $48,324,000.00 | ★ $234,603,000.00 |
| Revenue This Year | $16.01 | N/A |
| Revenue Next Year | $11.31 | $52.14 |
| P/E Ratio | $469.20 | ★ N/A |
| Revenue Growth | 18.93 | ★ 157.01 |
| 52 Week Low | $10.96 | $17.11 |
| 52 Week High | $24.02 | $73.30 |
| Indicator | CDNA | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 65.75 | 43.43 |
| Support Level | $15.80 | $53.46 |
| Resistance Level | N/A | $57.70 |
| Average True Range (ATR) | 1.04 | 2.61 |
| MACD | 0.09 | -0.14 |
| Stochastic Oscillator | 93.00 | 35.23 |
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).